What is Clomipramine?
Clomipramine is a non-selective serotonin reuptake inhibitor (tricyclic antidepressant) primarily used for obsessive-compulsive disorder, distinguished by its potent serotonergic activity but limited to second-line treatment due to inferior safety and tolerability compared to SSRIs. 1
Mechanism of Action
Clomipramine works by blocking the reuptake of serotonin (5-HT), which is thought to be the key mechanism for reducing obsessive-compulsive behaviors 2. Unlike selective SSRIs, clomipramine is a non-selective serotonin reuptake inhibitor 1. Its active metabolite, desmethylclomipramine, is a potent norepinephrine reuptake inhibitor, adding to its pharmacological complexity 2, 3.
Clinical Indications
Primary Indication: Obsessive-Compulsive Disorder
- Clomipramine was the first medication proven effective for OCD 1, 4
- It is positioned as a second-line or third-line agent in modern treatment algorithms 1
- Used when:
- SSRIs have failed (after trying at least one or two SSRIs)
- As augmentation therapy with SSRIs in treatment-resistant cases
- Before considering neurosurgery (must trial three SRIs including clomipramine) 1
Historical Context
While meta-analyses suggested clomipramine might be more efficacious than SSRIs, head-to-head trials show equivalent efficacy 1. The apparent superiority in older meta-analyses is misleading because clomipramine trials were conducted earlier on less treatment-resistant patients 1.
Other Uses
Clomipramine has been used for depression, resistant depression, phobias, panic disorder, chronic pain, and other conditions 5, though OCD remains its FDA-approved indication in the United States.
Dosing Guidelines
Pharmacokinetics
- Bioavailability: Well absorbed orally, but undergoes significant first-pass metabolism (bioavailability <62%) 2, 3
- Protein binding: 90-98% (approximately 97%) 2, 3
- Half-life: ~24 hours for clomipramine; ~96 hours for desmethylclomipramine 6
- Time to steady-state: Approximately 3 weeks 6
- Peak plasma levels: 2-6 hours after oral dose 2
Dosing Strategy
- Effective doses: Typically >75 mg/day 3
- Maximum recommended dose: 250 mg/day 3
- Trial duration: 8-12 weeks at maximum tolerated dose to assess efficacy 1
- Maintenance: Minimum 12-24 months after remission, often longer due to relapse risk 1
Important Pharmacokinetic Considerations
- Non-linear kinetics: Desmethylclomipramine exhibits non-linear pharmacokinetics over usual dosing ranges 2
- At 200 mg doses, plasma concentrations can reach up to 605 ng/mL for clomipramine and 781 ng/mL for desmethylclomipramine 2
- Therapeutic range: Blood concentrations <150 mcg/L associated with non-response; >450 mcg/L rarely improve efficacy 6
Contraindications (FDA Label)
Absolute Contraindications 2:
- Hypersensitivity to clomipramine or other tricyclic antidepressants
- MAOI use: Within 14 days before or after clomipramine (risk of serotonin syndrome)
- Linezolid or IV methylene blue: Cannot start clomipramine in patients receiving these agents
- Acute myocardial infarction: Contraindicated during acute recovery period
Critical Safety Concerns
Why SSRIs Are Preferred First-Line
SSRIs have a superior safety and tolerability profile compared to clomipramine, making them advantageous for long-term treatment 1. This is the primary reason clomipramine is relegated to second-line status despite potential efficacy.
Major Adverse Effects
- Anticholinergic effects: Urinary retention (documented case requiring catheterization) 7, dry mouth, constipation
- Cardiovascular: Arrhythmias, particularly concerning in overdose 3
- Gastrointestinal: Initial GI symptoms 1
- Sexual dysfunction 1
- CNS effects 3
- Seizures: Risk increases with higher doses 1
Dangerous Drug Interactions
When combining clomipramine with SSRIs (augmentation strategy), there is significant risk of elevated blood levels of both drugs, potentially causing seizures, cardiac arrhythmias, and serotonin syndrome 1. Despite this risk, fluoxetine plus clomipramine was superior to fluoxetine plus quetiapine in SSRI-resistant OCD 1.
Special Populations
- Genetic polymorphism: Patients deficient in hydroxylation (cytochrome P450 polymorphism) accumulate desmethylclomipramine to dangerous levels 6
- Elderly: Require lower doses due to reduced demethylation and hydroxylation 6
- Drug interactions: Phenothiazines can cause serious accumulation; smoking induces demethylation; chronic alcohol reduces this pathway 6
Clinical Positioning
In the modern OCD treatment algorithm 1:
- First-line: CBT or SSRIs
- Inadequate response: Combine SSRI + CBT, or switch SSRIs
- Second-line: Clomipramine (as monotherapy or augmentation)
- Third-line: Antipsychotic augmentation, glutamate modulators, neuromodulation
- Last resort: Neurosurgery (only after three SRIs including clomipramine, adequate CBT, and disease incapacitation)
The key clinical pitfall is using clomipramine too early in the treatment algorithm when safer SSRIs have not been adequately trialed, or failing to monitor for the serious drug interactions and adverse effects that make this medication more dangerous than modern alternatives.